Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Enochian Biosciences Inc (ENOB)

Enochian Biosciences Inc (ENOB)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.7000 unch (unch) 08/04/23 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 0.7000 unch (unch) -
Quote Overview for Fri, Aug 4th, 2023
Day Low
0.7000
Day High
0.7500
Open 0.7300
Previous Close 0.7000 0.7000
Volume 88,300 88,300
Avg Vol 436,705 436,705
Stochastic %K 68.87% 68.87%
Weighted Alpha -71.44 -71.44
5-Day Change +0.1294 (+22.68%) +0.1294 (+22.68%)
52-Week Range 0.3928 - 2.9900 0.3928 - 2.9900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,799
  • Shares Outstanding, K 58,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -113,430 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.59
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.08 on 05/12/23
  • Next Earnings Date 08/11/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4210 +66.27%
on 07/06/23
Period Open: 0.5034
0.7638 -8.35%
on 08/01/23
+0.1966 (+39.05%)
since 07/03/23
3-Month
0.3928 +78.21%
on 06/29/23
Period Open: 1.2100
1.2800 -45.31%
on 05/05/23
-0.5100 (-42.15%)
since 05/04/23
52-Week
0.3928 +78.21%
on 06/29/23
Period Open: 2.8000
2.9900 -76.59%
on 08/08/22
-2.1000 (-75.00%)
since 08/04/22

Most Recent Stories

More News
Renovaro BioSciences (NASDAQ: RENB) Releases CEO Shareholder Message

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released...

NVDA : 111.01 (+4.30%)
RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Featured in Recent Proactive Interview

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured...

RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Releases Shareholder Letter

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, is sharing a...

RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Enters Definitive Agreement to Combine with Leading AI Tech GEDi Cube

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has inked...

RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released...

NVDA : 111.01 (+4.30%)
RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Eyes Clear Path to IND Submission for Cancer Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in...

RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) CEO Discusses Product Development in Letter to Shareholders

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development...

RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB) Eyes Bright Future in Advancing Potentially Curative Therapies

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), is focused on advancing treatments for some of the world’s deadliest diseases. In late 2022, the company announced the award of a U.S. patent...

RENB : 0.3732 (+0.11%)
ENOB : 0.7000 (unch)
Renovaro BioSciences (NASDAQ: RENB), GEDi Cube Announce LOI to Merge, Focus on Fight Against Cancer

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, and...

RENB : 0.3732 (+0.11%)
INTC : 20.05 (-6.70%)
ORCL : 138.49 (+0.71%)
ENOB : 0.7000 (unch)
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

/PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Enochian Biosciences,...

ENOB : 0.7000 (unch)
ENOCHIAN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Enochian Biosciences, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Enochian Biosciences, Inc. (“Enochian” or the...

ENOB : 0.7000 (unch)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Enochian Biosciences, Inc. (ENOB)

The Law Offices of Frank R. Cruz reminds investors of the upcoming September 26, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Enochian...

ENOB : 0.7000 (unch)
ENOB SHAREHOLDER ALERT: Jakubowitz Law Reminds Enochian Shareholders of a Lead Plaintiff Deadline of September 26, 2022

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Enochian BioSciences, Inc....

ENOB : 0.7000 (unch)
ENOB LAWSUIT ALERT: Levi & Korsinsky Notifies Enochian BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Enochian BioSciences, Inc. ("Enochian" or the "Company") (NASDAQ: ENOB) of a class action...

ENOB : 0.7000 (unch)
ENOB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 26, 2022 in the Class Action Filed on Behalf of Enochian BioSciences, Inc. Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Enochian BioSciences, Inc. (NASDAQ:...

ENOB : 0.7000 (unch)
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Enochian Investors of a Lead Plaintiff Deadline of September 26, 2022

/PRNewswire/ -- Attention Enochian BioSciences, Inc. ("Enochian") (NASDAQ: ENOB) shareholders: The Law Offices of Vincent Wong announce that a class action...

ENOB : 0.7000 (unch)
ENOB FINAL DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action - ENOB

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB)...

ENOB : 0.7000 (unch)
ENOB SHAREHOLDER ALERT: Jakubowitz Law Reminds Enochian Shareholders of a Lead Plaintiff Deadline of September 26, 2022

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Enochian BioSciences, Inc....

ENOB : 0.7000 (unch)
ENOB LAWSUIT ALERT: Levi & Korsinsky Notifies Enochian BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Enochian BioSciences, Inc. ("Enochian" or the "Company") (NASDAQ: ENOB) of a class action...

ENOB : 0.7000 (unch)
ENOB FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Enochian BioSciences, Inc. Investors to Secure Counsel Before Important September 26 Deadline in Securities Class Action - ENOB

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Enochian BioSciences, Inc. (NASDAQ: ENOB)...

ENOB : 0.7000 (unch)

Business Summary

Enochian BioSciences Inc. engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the human treatment of HIV and cancer. The company's product pipeline consists of ENO-1001, ENO-2001, ENO-3001, ENO-1002, ENO-5001 and ENO-4001. Enochian...

See More

Key Turning Points

3rd Resistance Point 0.7833
2nd Resistance Point 0.7667
1st Resistance Point 0.7333
Last Price 0.7000
1st Support Level 0.6833
2nd Support Level 0.6667
3rd Support Level 0.6333

See More

52-Week High 2.9900
Fibonacci 61.8% 1.9979
Fibonacci 50% 1.6914
Fibonacci 38.2% 1.3849
Last Price 0.7000
52-Week Low 0.3928

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective